ClinicalTrials.gg
RecruitingNCT06532006Updated Feb 27, 2026

A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer

A Phase 3 interventional study of HLX22 and Pembrolizumab in Gastroesophageal-junction Cancer, Monoclonal Antibody and Gastric Cancer, sponsored by Shanghai Henlius Biotech. Recruiting at 208 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by Shanghai Henlius Biotech (part of Fosun Pharma) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
550
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 1,184 studies in Stomach Neoplasms with a site in China — 481 open to participants now, 557 under way, 50 of them phase 3. Stomach Neoplasms · China.

Planned enrollment
115th of 881
550 · median 87
Started
2024
with 140 others
Phase 3
122 of 1,184
33 open now
Primary completion
2027-06
later than 374 of 556 live
Registered
879th of 1,184
by date

Among the 1,184 studies in Stomach Neoplasms with a site in China, this one is the 115th largest by planned enrollment of the 881 interventional ones that give a count, is one of 141 that started in 2024, is one of 122 in phase 3, reaches primary completion later than 374 of the 556 other live ones, and was the 879th registered.

Stomach Neoplasms

3,403 studies on the registry are indexed under Stomach Neoplasms; 993 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

481 of the 1,184 studies in Stomach Neoplasms with a site in China are open now. Recruiting first, the newest first:

476 more — sign in →

All 481 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,184 studies in Stomach Neoplasms with a site in China, or all of them as a file.
02

Study summary

This is a double-blind, randomized, multiregion, comparative phase Ⅲ clinical study designed to evaluate the efficacy and safety of HLX22 in combination with trastuzumab and chemotherapy as first-line treatment in patients with HER2-positive locally advanced/metastatic adenocarcinoma of the gastric and/or gastroesophageal junction (G/GEJ).Eligible subjects will be randomized to the two groups based on a 1:1 ratio. Enrolled subjects shall be treated with the study drug until the loss of clinical benefit, death, intolerable toxicity, withdrawal of informed consent, or other reasons specified by the protocol (whichever occurs first).

Read the detailed description

In experimental group: HLX22 (15 mg/kg) + trastuzumab + chemotherapy (XELOX) ± placebo (for pembrolizumab), once every 3 weeks (Q3W).

In control group: Placebo (for HLX22) + trastuzumab + chemotherapy (XELOX) ± pembrolizumab, Q3W.

03

Conditions studied

  • Gastroesophageal-junction Cancer
  • Monoclonal Antibody
  • Gastric Cancer
  • HER2-positive Gastric Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male/female who are at least 18 years of age on the day of signing the .
  2. With or cytologically confirmed diagnosis of previously untreated, locally advanced unresectable or -positive gastric or gastroesophageal junction adenocarcinoma.
  3. Had as assessed by IRRC according to the v1.1, the target lesion must not be a bone metastatic lesion only.
  4. HER2-positive tumor defined as either IHC 3+ or IHC 2+ in combination with ISH+ or FISH, as assessed by a central laboratory on a primary or metastatic tumor.
  5. PS within 7 days before randomization: 0-1.
  6. Expected survival ≥ 6 months.
  7. Had adequate organ function

Exclusion criteria

Exclusion Criteria:

  1. Patients with other malignant tumors within 2 years before the randomization.
  2. Evidence of disease progression within 6 months (before randomization) after completion of prior or adjuvant chemotherapy (or both) or radiotherapy for gastric adenocarcinoma or gastroesophageal junction adenocarcinoma.
  3. Previous treatment with any -target therapy.
  4. Active gastrointestinal bleeding
  5. Presence of central nervous system (CNS) .
  6. (LVEF) \< 55%.
  7. Subjects who had known history of severe allergy to any monoclonal antibody or any component of study treatment.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
550 participants (estimated)

Study arms

  • Experimental
    Experimental group

    Experimental group: HLX22 (15 mg/kg) + trastuzumab + chemotherapy (XELOX) ± placebo (for pembrolizumab), Q3W Subjects in the experimental group may use one of the treatments below: HLX22 (15 mg/kg) + trastuzumab + chemotherapy (XELOX) or HLX22 (15 mg/kg) + trastuzumab + chemotherapy (XELOX) + placebo (for pembrolizumab)

    Drug: HLX22 · Drug: Trastuzumab · Drug: Oxaliplatin · Drug: Capecitabine

  • Active comparator
    Control group

    Control group: Placebo (for HLX22) + trastuzumab + chemotherapy (XELOX) ± pembrolizumab, Q3W Subjects in the control group may use one of the treatments below: Placebo (for HLX22) + trastuzumab + chemotherapy (XELOX) or Placebo (for HLX22) + trastuzumab + chemotherapy (XELOX) + pembrolizumab

    Drug: Pembrolizumab · Drug: Trastuzumab · Drug: Oxaliplatin · Drug: Capecitabine

Interventions

  • DrugHLX22

    HLX22 15mg/kg Q3w

  • Pembrolizumab 200mg q3w

  • Trastuzumab 8 mg/kg loading dose and then 6 mg/kg maintenance thereafter ,Q3W

  • Oxaliplatin 130 mg/m2 ,Q3W

  • Capecitabine 1000 mg/m2 bid on Days 1-14 ,Q3W

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS)per RECIST 1.1 assessed by IRRC(Independent Radiology Review Committee)

    PFS is defined as the time from randomization to the first documented disease progression per RECIST 1.1 or death due to any cause, whichever occurs first. PFS will be determined for each treatment arm

    Time frame: Up to 5 years

  2. Overall Survival (OS)

    OS is defined as the time from randomization to death due to any cause. OS will be determined for each treatment arm.

    Time frame: Up to 5 years

Secondary outcomes

  1. PFS per RECIST 1.1 assessed by investigator

    PFS is defined as the time from randomization to the first documented disease progression per RECIST 1.1 or death due to any cause, whichever occurs first. PFS will be determined for each treatment arm

    Time frame: Up to 5 years

  2. Objective Response Rate (ORR) assessed by IRRC and investigator per RECIST v1.1

    ORR is defined as the percentage of participants who have a Complete Response (\[CR\], disappearance of all evidence of disease) or Partial Response (\[PR\], regression of measurable disease and no new sites) per RECIST 1.1. ORR will be determined for each treatment arm.

    Time frame: Up to 5 years

  3. Adverse events (AE)

    An AE is any untoward medical occurrence in a participant that is temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment. The number of participants who experience an AE will be reported for each treatment arm.

    Time frame: Up to 5 years

07

Study locations

207 of 208 sites recruiting
  • Los Angeles Cancer Network
    Anaheim, California 92801, United States
    Recruiting
  • OPN - Oncology Physician Network (Los Alamitos)
    Los Alamitos, California 90720, United States
    Recruiting
  • Banner MD Anderson Cancer Center
    Greeley, Colorado 80631, United States
    Recruiting
  • Advanced Research LLC
    Deerfield Beach, Florida 33064, United States
    Recruiting
  • Florida Cancer Specialist - South
    Fort Myers, Florida 33901, United States
    Recruiting
  • BRCR Medical Center
    Plantation, Florida 33322, United States
    Recruiting
  • Napa Research
    Pompano Beach, Florida 33064, United States
    Recruiting
  • Florida Cancer Specialist - North
    St. Petersburg, Florida 33705, United States
    Recruiting
  • Florida Cancer Specialist - East
    West Palm Beach, Florida 33401, United States
    Recruiting
  • Northwestern University
    Chicago, Illinois 60611, United States
    Recruiting
  • University of Chicago
    Chicago, Illinois 60637, United States
    Recruiting
  • Mission Cancer + Blood (Exigent Network)
    Des Moines, Iowa 50309, United States
    Recruiting
  • Holden Comprehensive Cancer Center - University of Iowa
    Iowa City, Iowa 52242, United States
    Recruiting
  • Washington University School of Medicine St. Louis
    St Louis, Missouri 63110, United States
    Recruiting
  • Nebraska Cancer Specialists
    Omaha, Nebraska 68130, United States
    Recruiting
  • Comprehensive Cancer Centers Nevada
    Las Vegas, Nevada 89169, United States
    Recruiting
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
    Recruiting
  • UPMC Hillman Cancer Center
    Pittsburgh, Pennsylvania 15232, United States
    Recruiting
  • Guthrie Medical Group, PC and Robert Packer Hospital (Guthrie Cancer Center - Sayre)
    Sayre, Pennsylvania 18840, United States
    Recruiting
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
    Recruiting
  • HCA Midwest Health
    Nashville, Tennessee 60637, United States
    Recruiting
  • Texas Oncology - West (SCRI)
    Abilene, Texas 79606, United States
    Recruiting
  • Texas Oncology Central South (SCRI)
    Austin, Texas 78705, United States
    Recruiting
  • Texas Oncology Northeast (SCRI)
    Denton, Texas 76201, United States
    Recruiting
  • The University of Texas MD Anderson cancer Center
    Houston, Texas 77030, United States
    Recruiting
  • Texas Oncology - Gulf Coast (SCRI)
    Webster, Texas 77598, United States
    Recruiting
  • American Oncology Network Vista Oncology Division
    Olympia, Washington 98502, United States
    Recruiting
  • Northwest Medical Specialties
    Tacoma, Washington 98405, United States
    Recruiting
  • West Virginia University Cancer Institute
    Morgantown, West Virginia 26506, United States
    Recruiting
  • Centro de Investigacion Pergamino SA
    Buenos Aires, Buenos Aires B2700, Argentina
    Recruiting
  • União Brasileira de Educação e Assistência
    Puerto Alegre, RS 90610000, Argentina
    Recruiting
  • Centro de Investigaciones Clinicas. Clinica Viedma S.A.
    Viedma, Río Negro Province 8500, Argentina
    Recruiting
  • Instituto de Oncologia de Rosario
    Cordoba, Santa Fe Province 2000, Argentina
    Recruiting
  • Centro Médico Privado CEMAIC
    Cordoba, Santa Fe Province X5008HHW, Argentina
    Not yet recruiting
  • Sanatorio Plaza - Fundacion Pita
    Rosario, Santa Fe Province 2000, Argentina
    Recruiting
  • Sanatorio de la Mujer
    Rosario, Santa Fe Province S2013, Argentina
    Recruiting
  • Beneficência Portuguesa de São Paulo
    San Pablo, SP 01321-001, Argentina
    Recruiting
  • Fundacion CENIT
    Buenos Aires, 1125, Argentina
    Recruiting
  • IONC Instituto Oncologico de Cordoba
    Córdoba, 5000, Argentina
    Recruiting
  • Instituto San Marcos
    San Juan, J5400 EBB, Argentina
    Recruiting
  • CER - Centro de Rehabilitacion Medica San Juan
    San Juan, J5402 DIL, Argentina
    Recruiting
  • Exelsus
    San Miguel de Tucumán, 4000, Argentina
    Recruiting
  • St. Vincent Hospital Melbourne
    Fitzroy, Melbourne 3065, Australia
    Recruiting
  • Peninsula Health-Frankston hospital
    Frankston, Melbourne 3940, Australia
    Recruiting
  • University of the Sunshine Coast Clinical Trials, Sunshine Coast Haematology and Oncology Clinic
    Sunshine Coast, Queensland 4556, Australia
    Recruiting
  • GenesisCare Research
    Campbelltown, Sydney 2560, Australia
    Recruiting
  • Central Coast Local Health District (Gosford and Wyong Hospital)
    Gosford, Sydney 2250, Australia
    Recruiting
  • Macquarie University
    North Ryde, Sydney 2109, Australia
    Recruiting
  • Concord Repatriation General Hospital
    Concord, Sydney, Australia
    Recruiting
  • Personal Oncologia de Precisio e Personalizada
    Belo Horizonte, Minas Gerais 30130 090, Brazil
    Recruiting
  • Instituto de Oncologia do Paraná - IOP Pequisa
    Curitiba, Paraná (PR) 82305-100, Brazil
    Recruiting
  • Real Hospital de Beneficencia Portuguesa
    Recife, Pernambuco 52010-075, Brazil
    Recruiting
  • Hospital de Clinicas de Porto Alegre (HCPA)
    Porto Alegre, Rio Grande do Sul 90035-903, Brazil
    Recruiting
  • Centro Gaúcho Integrado - Hospital Mãe de Deus
    Porto Alegre, Rio Grande do Sul 90110-270, Brazil
    Recruiting
  • Clinica de Hematologia e Oncologia Viver
    Santa Maria, Rio Grande Do Sul (RS) 97015-450, Brazil
    Recruiting
  • ANIMI - Unidade de Tratamento Oncologico
    Lages, Santa Catarina 88501-003, Brazil
    Recruiting
  • Brazilian Institute for Cancer Control (IBCC)
    Vila Mariana, São Paulo 04014-002, Brazil
    Recruiting
  • Hospital Santa Marcelina HSM
    São Paulo, 08270-120, Brazil
    Recruiting
  • Centro de Oncologia de Precision
    Santiago, Santiago Metropolitan 7560908, Chile
    Recruiting
  • Instituto del Cancer RedSalud Vitacura
    Santiago, Santiago Metropolitan 7630000, Chile
    Recruiting
  • Icegclinic
    Santiago, 8240000, Chile
    Recruiting
  • Fundacion Arturo Lopez Perez
    Santiago, 99010-080, Chile
    Recruiting
  • Affiliated Hospital of Youjiang Medical University for Nationalities
    Baise City, China
    Recruiting
  • Beijing Cancer Hospital
    Beijing, 100142, China
    Recruiting
    • Lin Shen · Principal investigator
  • Cancer Hospital Chinese Academy of Medical Sciences
    Beijing, China
    Recruiting
  • Peking Union Medical College Hospital
    Beijing, China
    Recruiting
  • The First Affiliated Hospital of Bengbu Medical University
    Bengbu, China
    Recruiting
  • The First Hospital of Jilin University
    Changchun, China
    Recruiting
  • Hunan Cancer Hospital
    Changsha, China
    Recruiting
  • Heping Hospital Affiliated to Changzhi Medical College
    Changzhi, China
    Recruiting
  • The First People's Hospital of Changzhou
    Changzhou, China
    Recruiting
  • Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital
    Chengdu, China
    Recruiting
  • West China Hospital of Sichuan University
    Chengdu, China
    Recruiting
  • The First Affiliated Hospital of Chongqing Medical University
    Chongqing, China
    Recruiting
  • Dezhou Second People's hospital
    Dezhou, China
    Recruiting
  • Fujian Cancer Hospital
    Fuzhou, China
    Recruiting
  • Zhongshan City People's Hospital
    Guangdong, China
    Recruiting
  • The Sixth Affiliated Hospital of Sun Yat-sen University
    Guangzhou, China
    Recruiting
  • Sir Run Run Shaw Hospital (SRRSH), affiliated with the Zhejiang University School of Medicine
    Hangzhou, China
    Recruiting
  • The First Affiliated Hospital, Zhejiang University School of Medic
    Hangzhou, China
    Recruiting
  • Harbin Medical University Cancer Hospital
    Harbin, China
    Recruiting
  • The First Affiliated Hospital of Anhui Medical University
    Hefei, China
    Recruiting
  • The Second Hospital of Anhui Medical University
    Hefei, China
    Recruiting
  • Cancer Hospital of Shandong First Medical University
    Jinan, China
    Recruiting
  • Gansu Provincial Cancer Hospital
    Lanzhou, China
    Recruiting
  • Gansu Provincial Hospital
    Lanzhou, China
    Recruiting
  • Gansu Wuwei Tumour Hospital
    Lanzhou, China
    Recruiting
  • The First Hospital Of Lanzhou University
    Lanzhou, China
    Recruiting
  • Liuzhou Workers' Hospital
    Liuzhou, China
    Recruiting
  • The First Affiliated Hospital of Henan University of Science
    Luoyang, China
    Recruiting
  • Mianyang Central Hospital
    Mianyang, China
    Recruiting
  • The First Affiliated Hospital of Nanchang University
    Nanchang, China
    Recruiting
  • Jiangsu Province Hospital
    Nanjing, China
    Recruiting
  • Nanjing Drum Tower Hospital
    Nanjing, China
    Recruiting
  • The Affiliated Hospital of Qingdao University
    Qingdao, China
    Recruiting
  • Fudan University Shanghai Cancer Center
    Shanghai, China
    Recruiting
  • Renji Hospital,Shanghai Jiao Tong University School of Medicine
    Shanghai, China
    Recruiting
  • The Central Hospital of Shaoyang
    Shaoyang, China
    Recruiting
  • Liaoning Medical University Cancer Institute & Hospital
    Shenyang, China
    Recruiting
  • The Fourth Hospital of Hebei Medical University
    Shijia Zhuang, China
    Recruiting

Showing the first 100 of 208 sites across 17 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Jun 2027, 30 months after the start.

Of 45 industry-sponsored phase 3 interventional studies under Stomach Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 55. This study's planned 30 months is below that.

Counting every sponsor, half of 118 studies reached it within 52 months; a quarter within 39 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2024
First posted
Aug 1, 2024
StartActual
Nov 22, 2024
Primary completionEst.
Jun 1, 2027
CompletionEst.
Sep 1, 2028
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06532006
Collaborators
Henlius USA
Responsible party
Sponsor
First posted
Aug 1, 2024
Start date
Nov 22, 2024
Primary completion
Jun 1, 2027 (estimated)
Completion
Sep 1, 2028 (estimated)
Last update
Feb 27, 2026

Study contacts

Ying Li
Contact
ying_li1@henlius.com
+86 18810366427

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dulpatatug

Start the discussion